title: A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.
authors.forename: P O
authors.initials: PO
authors.lastname: Chappuis
authors.forename: J
authors.initials: J
authors.lastname: Goffin
authors.forename: N
authors.initials: N
authors.lastname: Wong
authors.forename: C
authors.initials: C
authors.lastname: Perret
authors.forename: P
authors.initials: P
authors.lastname: Ghadirian
authors.forename: P N
authors.initials: PN
authors.lastname: Tonin
authors.forename: W D
authors.initials: WD
authors.lastname: Foulkes
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D017239:Paclitaxel / Q000627:therapeutic use; D011300:Preoperative Care / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel